| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CTSO | Common Stock | Purchase | $34.8K | +16K | +2.13% | $2.17 | 766K | Jun 9, 2022 | Direct | F1, F2, F3, F4 |
| Id | Content |
|---|---|
| F1 | Reflects open market purchases made by the reporting person on June 9, 2022. Purchase price reflects the average price of purchases made in multiple transactions at prices ranging from $2.15 to $2.18, inclusive. The reporting person undertakes to provide full information regarding the number of shares purchased at each separate price within the range set forth herein upon request. |
| F2 | Includes (a) the following restricted stock units ("RSUs") that will be settled into shares of the Issuer's common stock upon vesting upon a "Change In Control" of the Issuer as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015; |
| F3 | (continued from footnote 2) (b) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of the Issuer's common stock upon vesting: 24,000 RSUs granted on April 12, 2021 and unvested on the date hereof; and |
| F4 | (continued from footnote 3) (c) 526,130 shares of the Issuer's common stock owned by the reporting person, inclusive of the 16,000 shares of the Issuer's common stock reported on this Form 4. |